Friday , June 24 2022

Tender of new Aids Aid that is due in December



[ad_1]

Six companies had registered three-in-one generic pills containing dolutegravir, tenofovir disoproxil fumarate and lamivudine with the Health Products Regulatory Agency SA, according to Pillay. The latest company to publish its product registration is Aspen Pharmacare's local pharmaceutical maker, who launched its version on Monday, Emdolten.

Originally, the current tender, valued at R14bn when announced in January 2015, came to an end in March, but it was extended by one year to allow companies to register products to make a competitive offer. There were also delays due to security concerns, as the interim findings of a small study in Botswana found that women who took dolomegravir during early pregnancy were at higher risk of fetal fetal neutral defects. All those findings still have to be confirmed when the final results of the study are published in 2019.

Dolutegravir offered significant benefits to public health as the probability of patients developing resistance was extremely low, said Francois Venter, deputy director of the Wits Foundation for Sexual Health and Reproductive, HIV and Related Diseases. Just under a million patients took dolutegravir-based regimens around the world, and no one had developed resistance so far, he said.

"That's pretty amazing," he added.

[email protected]

[ad_2]
Source link